GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies

Medicines considered critically important for patients to remain available

27-Jan-2015 - A number of medicines for which authorisation in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, says the European Medicines Agency (EMA). The recommendation is based on findings from an inspection that raised ...

GVK Biosciences announces multi-year drug discovery collaboration with the Moulder Center for Drug Discovery Research, Temple University

30-Nov-2011 - GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University. As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead ...

GVK Biosciences presented the Frost & Sullivan Growth Leadership Award in Contract Research Service Market

23-Nov-2011 - GVK Biosciences (GVK BIO) announced that it was awarded the Frost & Sullivan 2011 Best Practices Award for Growth Leadership in the Contract Research Services Market. The Frost & Sullivan Award for Growth Leadership is presented to the company that has demonstrated excellence in capturing an ...

GVK Biosciences receives AAALAC Accreditation for its Animal Facility

14-Jul-2010 - GVK Biosciences Private Limited (GVK BIO) announced that it received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International for its animal facilities. The accreditation demonstrates GVK BIO’s commitment to high standards of ...

GVK Biosciences appoints Dr. John Ellingboe as Senior Vice President, Discovery Chemistry

04-May-2010 - GVK Biosciences announced that Dr. John Ellingboe has been appointed as Senior Vice President, Discovery Chemistry. Dr. Ellingboe will report to Mr. Manni Kantipudi, President, GVK Biosciences. Prior to joining GVK BIO, Dr. Ellingboe worked with Wyeth Research and Pfizer for 25 years in senior ...

GVK Biosciences opens new Clinical Pharmacology Unit in Ahmedabad

New facility commissioned to meet increasing business demand

19-Mar-2010 - GVK Biosciences (GVK BIO) announced that it has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO’s existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers. Ahmedabad was the most ...

GVK Biosciences Joins ResearchPoint Global

Addition of India-based CRO expands reach of worldwide clinical organization

15-Jan-2010 - ResearchPoint Global (RPG) announced its newest member, GVK Biosciences (GVK BIO). GVK BIO provides RPG with access to an extensive network of experienced and proven investigative sites and country-specific regulatory, clinical and technical expertise. As the growth of India’s participation in ...

Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board

14-Dec-2009 - GVK Biosciences (GVK BIO) announced the appointment of Dr. Cecil B. Pickett as Scientific Advisor to the Board of Directors. Cecil B. Pickett, Ph.D. has served as President of Research and Development, and member of the Biogen Idec Board of Directors for three years (March 2006-October 2009). ...

GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to deliver Lead Molecules

02-Feb-2009 - GVK Biosciences (GVK BIO) and CRELUX announced that they have set-up a highly robust fragment-based drug discovery platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer-assisted drug design ...